1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag

Xintela: Focus on study results and financing

• Final study results support XSTEM’s disease-modifying potential in OA
• Rights issue of MSEK 72.8 announced at SEK 0.26 per share
• Q&A with CEO Evy Lundgren Åkerlund on the new Targinta collaboration

Xintela released its Q3 report on November 4 instead of the 21st as originally scheduled. The company delivered figures much in line with our expectations. A takeaway was a negative operating cash flow of 6.7 MSEK and a cash balance of MSEK 3.4. The financial situation was addressed a few days later when Xintela announced a preferential rights issue of MSEK 72.8.

We will await the outcome of the financing round before updating our forecast and revising the fair value. The full report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Datum 2025-11-12, kl 10:15
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!